Fact-checked by Grok 2 weeks ago

Glycoprotein

Glycoproteins are glycoconjugates in which one or more chains, known as , are covalently attached to a polypeptide backbone, typically via N- or **O-**linkages to residues such as , serine, or . These molecules represent a major class of proteins in eukaryotic s, with more than half of all eukaryotic proteins undergoing and approximately 90% of glycoproteins featuring N-linked modifications. The components can comprise a substantial portion of the glycoprotein's mass, often forming a dense protective layer called the on surfaces. The structure of glycoproteins is diverse, primarily determined by the type and site of glycan attachment. N-glycans are linked to the amide nitrogen of residues within the Asn-X-Ser/Thr (where X is any except ) and are synthesized via a lipid-linked precursor transferred en bloc to the protein in the ; they are classified into oligomannose, complex, and hybrid types based on processing in the Golgi apparatus. In contrast, O-glycans are attached to the hydroxyl oxygen of serine or (and occasionally other residues like tyrosine or hydroxylysine) through initial addition of (GalNAc) or other sugars, resulting in varied core structures that are elongated in the Golgi; prominent examples include mucin-type O-glycans, which form dense clusters on secreted and membrane-bound proteins. Additional linkage types, such as C-mannosylation (to ) and glypiation (via anchors), contribute to further structural heterogeneity. Glycoproteins perform essential biological functions across structural, metabolic, and informational roles. Structurally, glycans stabilize , protect against , and form barriers like the that regulate cell interactions. In energy , certain glycoproteins, such as those involved in storage, serve as nutrient reservoirs, while others influence processes like through sugar-based signaling. As information carriers, they mediate critical recognition events, including cell-cell via selectins, immune surveillance through mannose-binding , and pathogen-host interactions exemplified by viral hemagglutinins binding sialic acid-containing glycans. The physiological importance of glycoproteins extends to development, immunity, and disease, where dysregulation often leads to congenital disorders of glycosylation affecting protein trafficking and function. For instance, polysialic acid modifications on neural cell adhesion molecules modulate brain , while aberrant glycosylation contributes to cancer progression and immune evasion by pathogens through molecular mimicry. These molecules underscore the integration of carbohydrate and protein chemistries in eukaryotic , with ongoing research highlighting their therapeutic potential in design and .

Structure and Composition

Definition and General Structure

Glycoproteins are glycoconjugates in which one or more chains, known as glycans, are covalently attached to a polypeptide backbone, typically via linkages to the side chains of residues such as or . This attachment integrates moieties into the protein structure, creating hybrid molecules essential to numerous biological systems. The term "glycoprotein" was introduced in the early , building on earlier observations of carbohydrate-protein associations, with foundational studies on mucins—a class of heavily glycosylated proteins—conducted by Karl Meyer in the 1930s. At their core, glycoproteins consist of a central protein scaffold, or aglycone, adorned with diverse structures that impart significant heterogeneity. These are typically oligosaccharides composed of 1 to 60 units, arranged in linear or branched configurations that can include common sugars such as glucose, , , and . The branching often forms tree-like architectures, with the reducing end of the glycan linked to the protein and the non-reducing ends featuring terminal modifications that enhance structural diversity. This variability in glycan length, branching, and composition allows glycoproteins to adopt multiple glycoforms, even from the same polypeptide sequence, influencing properties like solubility and resistance to . The carbohydrate portion of glycoproteins generally accounts for 1–50% of the molecule's total mass by weight, though this proportion can vary widely depending on the specific glycoprotein. The protein core provides structural integrity and functional domains, such as enzymatic active sites or receptor-binding regions, while the attached glycans modulate overall conformation, , and interactions with the cellular . For instance, the hydrophilic of glycans often increases the protein's in aqueous media and protects it from aggregation or . This integrated architecture underscores the glycoprotein's role as a multifunctional entity, though detailed biological functions are explored elsewhere.

Glycan Attachment Sites

Glycans attach to proteins primarily through N-linked and , with additional sites in specific contexts such as . In N-linked , attachment occurs at the (Asn) residue within the consensus Asn-X-Ser/Thr, where X represents any except (Pro). This ensures specific recognition by the cellular machinery, restricting to solvent-accessible Asn residues in unfolded or partially folded proteins. For , glycans link to the hydroxyl groups of serine (Ser) or (Thr) residues, lacking a strict consensus sequence but often occurring in proline-rich or unstructured regions. Less commonly, targets hydroxylysine residues, particularly in , where post-translationally modified lysines serve as attachment points for galactosyl or glucosylgalactosyl groups. The chemical nature of these attachments involves distinct glycosidic bonds that dictate stability and protein interactions. The N-linked linkage forms a β-N-glycosidic bond between the amide nitrogen of Asn and the anomeric carbon of (GlcNAc), the initiating in this pathway. In contrast, O-linked attachments create an α-O-glycosidic bond between the hydroxyl oxygen of Ser or Thr and the anomeric carbon of (GalNAc) or, less frequently, (Gal). These bonds are covalent and resistant to under physiological conditions, enabling persistent glycan-protein conjugation. For hydroxylysine sites in , the linkage is also O-glycosidic, typically involving directly attached to the hydroxyl group. Glycan attachment sites exhibit considerable variability across proteins, with multiple potential sites often present but not always fully occupied. A single glycoprotein may harbor dozens of such sites, yet occupancy at each is modulated by local protein sequence features, such as flanking residues that influence accessibility, and by cellular machinery including glycosyltransferases whose expression and activity vary by and conditions. This partial occupancy contributes to glycan microheterogeneity, where even occupied sites display diverse glycan structures. These attachments profoundly influence and function by modulating conformation and intermolecular interactions. Glycans sterically hinder improper folding intermediates, promote proper assembly through hydrogen bonding and van der Waals contacts, and prevent aggregation by increasing and shielding hydrophobic regions. In particular, N-linked glycans reduce protein dynamics, enhancing rigidity in critical regions while facilitating chaperone-mediated quality control.

Common Monosaccharides

Glycoproteins in eukaryotes are primarily composed of a limited set of monosaccharides that serve as the fundamental building blocks for glycan chains, despite the existence of over 100 naturally occurring monosaccharides across all organisms. In mammalian systems, approximately nine to ten monosaccharides predominate in glycoprotein , including (GlcNAc), N-acetylgalactosamine (GalNAc), mannose (Man), galactose (Gal), fucose (Fuc), (primarily , Neu5Ac), and glucose (Glc), with occasional inclusion of others like (Xyl) and (GlcA). This restricted repertoire enables diverse glycan architectures through variations in linkage types and branching, while non-mammalian eukaryotes, such as and fungi, incorporate additional or alternative sugars like apiose or , and often feature unique modifications such as heptoses or 3-deoxy-D-manno-oct-2-ulosonic acid (Kdo). Monosaccharides are classified based on their chemical structures, which dictate their incorporation into glycans via glycosidic bonds. Hexoses, such as , , and Glc, are six-carbon aldoses that typically adopt or ring forms, providing the scaffold for core and branching elements in chains. Fuc represents a deoxyhexose, specifically 6-deoxy-L-galactose, lacking a hydroxyl group at the C6 position, which contributes to its compact structure and role in terminal modifications. Amino sugars like GlcNAc and GalNAc are derived from hexoses with an acetamido (-NHCOCH3) group at the position, enhancing polarity and serving as key initiators in pathways. Acidic sugars, exemplified by Neu5Ac, are nine-carbon derivatives featuring a carboxyl group (-COOH) that imparts a negative charge, often positioning them at glycan termini. These monosaccharides play distinct roles in assembling glycoprotein glycans. GlcNAc initiates N-linked glycosylation by being transferred to dolichol-phosphate on the cytoplasmic side of the , forming the base for subsequent en bloc transfer to residues. In contrast, GalNAc starts many O-linked chains, particularly mucin-type, through direct attachment to serine or by GalNAc-transferases in the Golgi apparatus. forms the core pentasaccharide in N-linked glycans (Man3GlcNAc2), providing branching points for further elaboration, while extends chains in complex-type N-glycans and O-glycans, contributing to linear or branched motifs. Neu5Ac caps terminal positions, conferring negative charge that enhances glycan stability and solubility through electrostatic repulsion. , often added to core or regions, facilitates specific molecular interactions by altering glycan conformation and recognition epitopes.
MonosaccharideCategoryKey Structural FeatureRole in Glycoprotein Glycans
N-Acetylglucosamine (GlcNAc)Amino sugarHexose with C2 acetamido groupInitiates N-linked chains on dolichol; core component.
N-Acetylgalactosamine (GalNAc)Amino sugarGalactose with C2 acetamido groupInitiates mucin-type O-linked chains.
Mannose (Man)HexoseSix-carbon aldose, pyranose ringForms N-linked core (Man3GlcNAc2); branching scaffold.
Galactose (Gal)HexoseSix-carbon aldose, pyranose ringExtends complex N- and O-glycans.
Fucose (Fuc)Deoxyhexose6-Deoxy-L-galactoseTerminal or core modification for interactions.
N-Acetylneuraminic acid (Neu5Ac)Acidic sugarNine-carbon with carboxyl groupTerminal capping for negative charge and stability.
Glucose (Glc)HexoseSix-carbon aldose, pyranose ringTemporary in N-linked precursor; trimmed during processing.

Types of Glycosylation

N-Linked Glycosylation

N-linked is a co-translational modification that occurs primarily in the (ER) of eukaryotic cells, where a pre-assembled precursor is transferred en bloc to the amide nitrogen of (Asn) residues within the consensus sequence Asn-X-Ser/Thr (where X is any except ). This process begins as the nascent polypeptide emerges into the ER lumen, approximately 10-15 residues from the signal sequence cleavage site, ensuring precise glycosylation of secretory and proteins. The precursor , Glc₃Man₉GlcNAc₂ (where Glc is glucose, Man is , and GlcNAc is ), is built stepwise on a lipid carrier, (Dol-PP), starting on the cytosolic face of the ER and flipping to the luminal side for completion with three glucose residues. The transfer is catalyzed by the (OST) complex, a multisubunit with at least eight subunits in mammals, including the catalytic subunit STT3A or STT3B, which recognizes the acceptor site and releases Dol-PP after ligation. Following transfer, the N-glycan undergoes maturation through sequential trimming and extension steps to generate diverse structures essential for protein folding, quality control, and function. In the ER, glucosidase I rapidly removes the outermost α1,2-linked glucose, followed by glucosidase II, which excises the remaining two glucoses; this monoglucosylated intermediate interacts with lectin chaperones calnexin and calreticulin to facilitate proper protein folding and retention of misfolded proteins via the unfolded protein response. Endoplasmic reticulum mannosidase I (ER Man I, encoded by MAN1B1) then trims one α1,2-linked mannose from each of the two upper branches, generating a Man₈GlcNAc₂ structure. Upon transport to the Golgi apparatus via COPII vesicles and receptors like LMAN1, further processing occurs: Golgi α-mannosidase I (MAN1A1 or MAN1A2) removes additional mannoses to yield Man₅GlcNAc₂, enabling action of N-acetylglucosaminyltransferase I (GnT-I, MGAT1), which adds a GlcNAc residue to expose the α1,6-mannose for subsequent modifications. In the medial and trans-Golgi, α-mannosidase II (MAN2A1) trims two more mannoses, allowing N-acetylglucosaminyltransferase II (GnT-II, MGAT2) to add another GlcNAc, followed by galactosyltransferases (e.g., B4GALT1) adding galactose to form N-acetyllactosamine units, and sialyltransferases (e.g., ST3GAL family) or fucosyltransferase 8 (FUT8) incorporating sialic acid (Neu5Ac) or fucose to the core or antennae. The resulting N-glycans fall into three main subtypes based on their branching and terminal modifications, reflecting the extent of processing. High-mannose N-glycans, retaining five to nine residues on the trimannosyl core (Man₅₋₉GlcNAc₂), predominate in early forms and certain lysosomal enzymes, often involved in rapid ER . N-glycans feature one high-mannose branch (with two to three mannoses) and one complex branch with GlcNAc and possibly , serving as intermediates in maturation. Complex N-glycans, the most elaborated subtype, contain the biantennary or tri-/tetra-antennary structures with terminal , , and sometimes , attached to the α1,3- and α1,6-linked mannoses of the core; these are prevalent on surface glycoproteins and immunoglobulins, influencing , trafficking, and . Defects in N-linked glycosylation enzymes or precursors lead to congenital disorders of glycosylation (CDG), a group of over 150 rare genetic syndromes characterized by underglycosylated serum and multisystem involvement. Type I CDGs arise from impairments in the dolichol-linked precursor assembly or function, such as phosphomannomutase 2 (PMM2) deficiency, the most common form, disrupting addition and causing psychomotor retardation, cerebellar atrophy, and . Type II CDGs result from Golgi processing defects, like MGAT2 mutations preventing complex N-glycan formation, leading to , seizures, and immune dysfunction. These disorders highlight the essential role of precise N-glycosylation in cellular , with some, like PMM2-CDG, partially treatable via supplementation to bypass metabolic blocks.

O-Linked Glycosylation

O-linked glycosylation involves the covalent attachment of oligosaccharides to the hydroxyl groups of serine or residues on proteins, primarily occurring in the Golgi apparatus. Initiation of this process is mediated by a of polypeptide N-acetylgalactosaminyltransferases (ppGalNAc-Ts), which transfer (GalNAc) from UDP-GalNAc to the target , forming an α-linkage. Over 20 isoforms of ppGalNAc-Ts exist in humans, each displaying unique substrate specificities that influence the selection of glycosylation sites based on local sequence and structure. Unlike , which utilizes a dolichol-linked precursor, O-linked initiation proceeds directly using nucleotide-activated sugars. Following initiation, the GalNAc serves as an acceptor for chain extension by sequential action of glycosyltransferases, resulting in diverse O-glycan structures. Common core structures include Core 1 (Galβ1-3GalNAcα-Ser/Thr), synthesized by Core 1 β1,3-galactosyltransferase (C1GALT1), and Core 2 (GlcNAcβ1-6(Galβ1-3)GalNAcα-Ser/Thr), which introduces branching via core 2 β1,6-N-acetylglucosaminyltransferase. These cores are further elaborated with monosaccharides such as galactose, fucose, and sialic acid, contributing to the structural heterogeneity of O-glycans. O-linked glycosylation encompasses several subtypes, with mucin-type being the most common, featuring dense clusters of GalNAc-initiated glycans on serine/threonine-rich domains of mucins and other proteins. Another subtype is O-mannosylation, where is directly linked to serine or , notably in α-dystroglycan, where it forms complex structures essential for interactions in muscle and brain tissues. O-fucosylation represents a specialized form, attaching to serine or threonine in epidermal growth factor-like repeats, critically regulating receptor-ligand interactions in developmental signaling pathways. A distinct form of O-linked modification, O-GlcNAcylation, occurs dynamically in the and , independent of the Golgi pathway. This involves the cycling of single residues added to serine or by O-GlcNAc (OGT) and removed by O-GlcNAcase (OGA), integrating nutrient sensing with signaling cascades such as regulation.

Other Glycosylation Types

Glypiation is the attachment of a (GPI) anchor that tethers proteins to the outer leaflet of the plasma membrane in eukaryotic cells. This involves the attachment of a preassembled to the α-carboxyl group of the C-terminal , typically , following cleavage of a . The conserved core structure of GPI consists of a linked to a residue, which is further connected via three units and an bridge to the protein, often represented as ethanolamine-P-Man₃GlcN-myoinositol-P-lipid. GPI-anchored proteins play roles in , , and pathogen-host interactions, with over 150 such proteins identified in humans. Defects in GPI anchor biosynthesis, particularly mutations in the PIGA gene required for the first step in GPI assembly, underlie (PNH), a clonal hematopoietic disorder leading to complement-mediated due to the absence of GPI-anchored complement regulators like CD55 and CD59. C-mannosylation is an uncommon variant characterized by the direct C-C linkage of an α-D- residue to the C2 position of the ring on residues within specific protein motifs. This modification occurs cotranslationally in the and is prevalent in thrombospondin type 1 repeats (TSRs) found in proteins such as thrombospondins and receptors. C-mannosylation promotes proper , enhances thermal and proteolytic stability, and facilitates by preventing aggregation during maturation. The process is catalyzed by protein O-mannosyltransferases that recognize the WXXW (where X is any ), with the derived from dolichol-linked precursors similar to those in O-mannosylation. P-glycosylation (phosphoglycosylation) involves the attachment of glycans to the phosphate group of residues and is a rare form observed primarily in prokaryotes, , and lower eukaryotes such as like . These phosphoglycans—consisting of mannose-galactose polymers—are covalently bound to serine via a phosphoester bond, contributing to surface formation and host evasion. Such modifications are initiated by phosphoglycosyltransferases that transfer sugar phosphates to target residues, enabling diverse assembly on bacterial glycoproteins involved in . Beyond N- and O-linked forms, glycosylation exhibits greater diversity in prokaryotes, with linkages to , phosphates, and non-standard supporting integrity and , whereas eukaryotic examples like GPI and C-mannosylation are evolutionarily conserved but limited in humans, highlighting their critical roles in specific disorders such as PNH. These atypical types occasionally share glycosyltransferases with O-linked pathways, facilitating coordinated assembly.

Functions

Biological Roles

Glycoproteins play crucial roles in various physiological processes by leveraging their glycan moieties to mediate interactions and maintain cellular integrity. In cell-cell recognition, s serve as ligands for , facilitating adhesion and communication between cells. For instance, selectins on endothelial cells bind to (sLeX)-bearing glycoproteins on leukocytes, enabling leukocyte rolling along vessel walls during immune responses. This interaction is essential for the initial recruitment of immune cells to sites of . In the (), glycoproteins contribute to structural support by enhancing protein stability and organization. , a major ECM component, undergoes that influences alignment and secretion, thereby promoting tissue architecture and mechanical strength. N-linked glycans on collagen further stabilize the matrix by mediating protein-protein interactions and protecting against degradation. Glycoproteins also provide protective functions at epithelial surfaces and in circulation. Mucins, heavily O-glycosylated proteins, form a viscous barrier that shields epithelia from mechanical stress and microbial invasion by trapping pathogens and preventing their adhesion. Similarly, serum glycoproteins such as (IgG) use their structures to modulate immune effector functions, such as and complement activation. These protective roles ensure barrier integrity and host defense. Beyond structural and protective duties, glycans on glycoproteins fine-tune signaling and enzymatic activities. In , N-glycosylation of the () regulates its ectodomain orientation, influencing dimerization and subsequent activation upon ligand binding. For enzymatic modulation, mannose-6-phosphate glycans on lysosomal enzymes direct their trafficking and enhance stability, thereby extending half-life and optimizing catalytic activity within lysosomes. These modifications are vital for efficient cellular and response to environmental cues.

Pathophysiological Implications

Altered patterns of glycoproteins play a pivotal role in various pathophysiological processes, contributing to disease progression, immune dysregulation, and therapeutic challenges. In cancer, aberrant sialylation and fucosylation are frequently observed, where hypersialylation shields tumor cells from immune surveillance and promotes by enhancing to endothelial surfaces via sialyl-Lewis antigens. For instance, elevated fucosylated structures like serve as a diagnostic in , correlating with advanced disease stages and poor . These modifications facilitate tumor invasion and immune evasion, underscoring their oncogenic significance. Congenital disorders of glycosylation (CDG) represent a group of inherited metabolic diseases arising from defects in glycan synthesis or attachment, leading to multisystemic impairments. The most common form, PMM2-CDG, results from mutations in the phosphomannomutase 2 gene, impairing N-linked and causing underglycosylated proteins that disrupt cellular functions. Clinically, PMM2-CDG manifests with severe neurological issues, including developmental delay, , and , often accompanied by coagulopathies and multi-organ failure due to defective glycoprotein trafficking and stability. In and , modulates immune responses and pathogen-host interactions. Hyposialylation of IgG Fc glycans in exacerbates by reducing anti-inflammatory properties and enhancing pro-inflammatory effector functions, such as . Conversely, in , viral glycoproteins like HIV-1 gp120 rely on dense N-linked for shielding immunogenic epitopes and facilitating viral entry into host cells via and co-receptor binding; this shield evades neutralizing antibodies, contributing to persistent . Dysregulated O-GlcNAcylation, an intracellular O-linked modification, links metabolic stress to aging and inflammatory diseases. In , elevates O-GlcNAc levels on key proteins like insulin signaling components, inducing and β-cell dysfunction, which perpetuate glucotoxicity and vascular complications. Similarly, in , incomplete O-glycosylation of leads to hyperphosphorylation and aggregation into neurofibrillary tangles, impairing stability and neuronal function, thereby accelerating neurodegeneration. Therapeutic glyco addresses these implications by modulating glycoprotein to mitigate in biologics. For monoclonal antibodies, afucosylated or sialylated Fc glycans enhances antibody-dependent cellular cytotoxicity while reducing unwanted immune activation, improving efficacy in and autoimmune treatments. Such strategies, including targeted inhibition in production cells, have demonstrated reduced anti-drug antibody responses in clinical settings, offering a pathway to safer protein therapeutics.

Synthesis and Processing

Endogenous Biosynthesis

The endogenous biosynthesis of glycoproteins in eukaryotic cells is a highly compartmentalized process that begins with protein and integrates as proteins traverse the secretory pathway. Protein synthesis occurs on ribosomes in the or associated with the rough (), where nascent polypeptides are translocated into the ER lumen for folding and modification. N-linked glycosylation is a co-translational event, initiated as the polypeptide emerges into the ER lumen, where oligosaccharyltransferase () transfers a preassembled from a dolichol-linked precursor to residues in the Asn-X-Ser/Thr (X ≠ Pro). In contrast, O-linked glycosylation is predominantly post-translational, occurring after protein synthesis and initial folding, with the addition of the first sugar (typically ) to serine or residues primarily in the Golgi apparatus. The serves as the primary site for initial glycoprotein processing, folding, and . Within the ER lumen, the / cycle facilitates proper folding by binding to monoglucosylated N-glycans on nascent glycoproteins, recruiting chaperones like ERp57 for bond formation and promoting iterative reglucosylation/deglucosylation by UDP-glucose:glycoprotein glucosyltransferase (UGGT) and I/II. This cycle ensures that only correctly folded proteins exit the , while misfolded ones are retained for refolding attempts. Further maturation occurs in the Golgi apparatus, where glycoproteins traffic from the cis-Golgi, through medial and trans stacks, to the trans-Golgi network; here, glycosyltransferases in distinct compartments extend and diversify chains into complex structures using nucleotide-activated sugars. Biosynthesis is energetically dependent on activated sugar donors, primarily UDP-sugars (e.g., UDP-GlcNAc, UDP-Gal) generated in the and transported into the /Golgi via specific nucleotide sugar transporters. For N-linked glycosylation, the dolichol cycle assembles the precursor Glc3Man9GlcNAc2-PP- on the : dolichol-phosphate is sequentially elongated with sugars from cytosolic and luminal sources, culminating in transfer by , with the dolichol cycle recycling the lipid carrier. O-linked glycosylation relies directly on UDP-GalNAc without a lipid intermediate. mechanisms prevent export of defective glycoproteins; misfolded proteins are recognized by ER stress sensors and targeted for ER-associated degradation (ERAD), where they are retrotranslocated to the via the Sec61 translocon and ubiquitinated by E3 ligases (e.g., HRD1) for proteasomal degradation. Incomplete or aberrant chains are trimmed by glycosidases and mannosidases, marking proteins for ERAD or lysosomal degradation to maintain cellular homeostasis.

Recombinant Production

Recombinant production of glycoproteins relies on heterologous expression systems to generate these complex biomolecules for therapeutic and research purposes, leveraging biotechnology to mimic or engineer glycosylation patterns essential for their function. Various host organisms are employed, each offering distinct advantages in yield, cost, and glycosylation fidelity. Bacterial systems, such as Escherichia coli, provide rapid, cost-effective production with high yields but lack endogenous glycosylation machinery, necessitating post-expression glycan attachment or pathway engineering for glycoprotein synthesis. Yeast systems, like Pichia pastoris, enable eukaryotic post-translational modifications including high-mannose N-linked glycans, supporting scalable secretion and densities up to hundreds of grams per liter of cell mass, though their hypermannosylation can limit applications. Mammalian cell lines, particularly Chinese hamster ovary (CHO) cells, produce human-like complex N-glycans with sialic acid capping, making them the gold standard for biopharmaceuticals due to compatibility with clinical use, albeit at higher costs and slower growth rates. Insect cell systems, often using baculovirus vectors in Sf9 or High Five cells, yield moderate glycosylation resembling paucimannose structures and support high expression of multi-subunit complexes, bridging cost and complexity. Plant-based systems, such as Nicotiana benthamiana, offer low-cost, large-scale production with homogeneous N-glycans but introduce plant-specific epitopes like β-1,2-xylose. A primary challenge in recombinant glycoprotein production is the generation of host-specific glycoforms that deviate from human patterns, potentially causing or altered ; for instance, -derived α-1,3-mannose linkages can trigger immune responses in humans. To address this, strategies involve targeted genetic modifications, such as knocking out undesired glycosyltransferases (e.g., FUT8 in cells to reduce fucosylation and enhance ) or knocking in human enzymes to install sialylated structures. These approaches, often based on principles from endogenous pathways, enable production of tailored glycoforms with improved homogeneity and bioactivity, as seen in strains engineered for over 90% terminal sialylation on . Scale-up of recombinant production typically occurs in bioreactors, where optimized fed-batch processes in mammalian or systems achieve titers of 1–10 g/L for monoclonal antibodies (with mammalian systems often reaching 5–10 g/L), facilitating gram-scale outputs for clinical . Recent advances since 2020 include CRISPR-edited cell lines for precise control, such as in cells to eliminate α-1,3-fucose or in to humanize N-glycans, yielding uniform glycoforms with reduced heterogeneity. In 2024, a method using secreted Glycocarriers in glycoengineered mammalian cells was developed for sustainable and scalable production of complex glycans and glycoproteins. Additionally, chemoenzymatic synthesis has emerged as a complementary method, using cell-free systems to assemble defined glycans on recombinant protein cores, bypassing host limitations for custom glycoprotein design.

Glycosylation Mechanisms

Glycosylation involves the action of glycosyltransferases (GTs), enzymes that catalyze the transfer of sugar moieties from activated donor molecules to acceptor proteins or . In humans, over 200 GT genes have been identified, encoded by the and classified into families based on sequence similarity and specificity. These enzymes are primarily Leloir-type GTs, which utilize nucleotide sugar donors such as UDP-GlcNAc or GDP-fucose, in contrast to non-Leloir GTs that employ alternative donors like or lipid-linked sugars, though the latter are less common in mammals. Complementary to GTs, glycosidases play a crucial role by trimming excess or immature sugar residues, particularly during N-linked glycan processing in the (ER) and Golgi, where enzymes like glucosidase I and II remove glucose units to facilitate proper folding and maturation. Regulation of glycosylation occurs at multiple levels, beginning with substrate availability, where are transported into the and Golgi lumens by specific nucleotide sugar transporters (NSTs), such as SLC35 family members, ensuring localized supply for GT activity. In the , chaperone proteins like and assist by binding to monoglucosylated N-glycans, promoting and through a cyclic that involves reglucosylation by UGGT. Feedback inhibition mechanisms further fine-tune the , as seen in the synthesis of nucleotide sugars where enzymes like GNE exhibit allosteric inhibition by end products such as CMP-Neu5Ac, preventing overaccumulation and maintaining flux balance. The dynamics of glycan assembly feature iterative addition in the Golgi apparatus, where GTs act sequentially across cis-, medial-, and trans-compartments, building complex structures through ordered substrate recognition and extension. A notable example is O-linked β-N-acetylglucosaminylation (O-GlcNAc), which serves as a sensor; elevated glucose levels increase UDP-GlcNAc production, boosting O-GlcNAc flux on nuclear and cytoplasmic proteins to modulate signaling pathways like insulin response. Defects in GTs often lead to congenital disorders of (CDGs), with mutations disrupting structures and causing multisystem diseases. For instance, FUT8 deficiency, which impairs core α1,6-fucosylation of N-glycans, results in emphysema-like changes, retardation, and immune dysregulation in fut8-/- models.

Examples and Applications

Natural Examples

Glycoproteins are integral components of membranes in various organisms, where they contribute to recognition and . A prominent example is the ABO blood group antigens expressed on the surface of erythrocytes, which are glycoproteins featuring residues attached to or , determining the A, B, AB, or O blood types through specific enzymatic additions. These antigens play a key role in immune by distinguishing self from non-self cells. Secreted glycoproteins, such as mucins, exemplify the protective and lubricating functions in epithelial tissues. Mucin 1 (MUC1), a transmembrane mucin heavily modified with O-linked glycans, is abundantly expressed in normal glandular epithelia but undergoes aberrant in , where truncated sialylated core structures predominate, altering its protective barrier properties and promoting tumor progression. In healthy contexts, MUC1's dense O-glycan coat provides lubrication and hydration in mucosal secretions, shielding underlying cells from mechanical stress and pathogens. Intracellular and membrane-associated glycoproteins also illustrate charge-mediated interactions in blood cells. Glycophorins, particularly (GPA), are major sialoglycoproteins on human red cells, bearing numerous residues on O-linked glycans that confer a net negative surface charge, essential for repelling adjacent cells and maintaining circulation stability. This sialylation, comprising up to 100 s per GPA molecule, supports the electrostatic repulsion that prevents aggregation in the bloodstream. In viral contexts, glycoproteins facilitate host-pathogen interactions. The (HA) protein of is a trimeric glycoprotein with multiple N-linked sites on its globular head domain, which shield antigenic epitopes and modulate receptor binding to sialic acid-containing glycans on host respiratory cells, enabling viral entry. These glycans, often complex-type in mammalian-adapted strains, evolve to evade immunity while preserving attachment to α2,6-linked sialic acids prevalent in human airways. Glycoproteins exhibit evolutionary conservation across domains of life, underscoring their ancient origins in cellular processes like and protection. They are ubiquitous in eukaryotes, with conserved N- and O- machinery facilitating diverse functions from to structural integrity. In prokaryotes, is simpler and less prevalent, often limited to surface proteins such as S-layer glycoproteins in , which lack the complex eukaryotic pathways but still contribute to stability and host interactions.

Hormonal Glycoproteins

Hormonal glycoproteins are a of glycoproteins that function as key endocrine signaling molecules, primarily within the reproductive and thyroid axes. These hormones, including (FSH), (LH), (TSH), and (hCG), are heterodimers composed of a common α-subunit and a hormone-specific β-subunit, both extensively with N-linked glycans. The is essential for their proper folding, , bioactivity, and , distinguishing them from their non-glycosylated counterparts, which act as antagonists. The glycan structures on these hormones significantly influence their circulatory half-life and tissue targeting. Sialic acid residues, particularly α2,3- or α2,6-linked, cap the terminal glycans and prevent recognition by the hepatic asialoglycoprotein receptor (ASGR), thereby protecting desialylated (asialo) forms from rapid clearance by the liver. For instance, in FSH, highly sialylated isoforms exhibit extended half-lives (up to 17 hours for the terminal phase), enhancing sustained ovarian stimulation, while less sialylated forms are cleared more quickly. Similarly, LH and TSH sialylation modulates their plasma persistence, with desialylated variants showing accelerated hepatic uptake and reduced bioactivity. hCG, unique among these due to its C-terminal peptide extension on the β-subunit, has the longest half-life (24-33 hours), further prolonged by placental sialylation patterns that differ from pituitary-derived forms, such as those in gonadotropins. These isoform variations—e.g., more branched, sialylated glycans in placental hCG versus pituitary FSH/LH—arise from source-specific glycosyltransferase expression and affect receptor binding affinity and downstream signaling. Regulation of hormonal glycoprotein production and glycosylation occurs primarily in pituitary gonadotropes and thyrotropes, stimulated by (GnRH) for FSH and LH. Pulsatile GnRH binding to its receptor triggers intracellular signaling cascades, including calcium mobilization, that coordinate subunit synthesis, assembly, and post-translational in the and Golgi apparatus. GnRH pulse frequency influences glycan complexity; rapid pulses favor less sialylated LH isoforms for acute action, while slower pulses promote more sialylated FSH forms for prolonged effects. Defects in this pathway, such as GnRH receptor mutations or impaired pulsatility, lead to , characterized by reduced secretion, aberrant , and due to insufficient and steroidogenesis. For TSH, (TRH) similarly regulates in thyrotropes, with disruptions contributing to dysfunction. Clinically, these insights underpin therapeutic interventions, particularly recombinant versions mimicking natural glycoforms. Follitropin alfa, a recombinant FSH produced in ovary cells with sialylation profiles akin to pituitary FSH, is widely used for in assisted , improving and pregnancy rates in anovulatory . Recombinant hCG and LH (e.g., choriogonadotropin alfa and lutropin alfa) are employed similarly, with their glycan-dependent half-lives optimized for follicular maturation and luteal support. These biopharmaceuticals address deficiencies in conditions like , highlighting the translational impact of glycoprotein hormone biology.

Therapeutic and Industrial Uses

Glycoproteins are integral to modern therapeutics, particularly in the form of monoclonal antibodies (mAbs) where modulates effector functions such as (ADCC). For example, (Herceptin), an mAb approved for HER2-positive , relies on Fc N-glycans to facilitate ADCC by binding to FcγRIIIa receptors on immune cells; remodeling these glycans, such as through afucosylation, can enhance this activity up to 100-fold in preclinical models. Similarly, bisected N-glycans, featuring an additional GlcNAc residue on the core , have been engineered into mAbs to improve affinity and therapeutic potency, as shown in glycoengineered variants that boost ADCC without altering specificity. Another key therapeutic glycoprotein is (EPO), a hormone that stimulates production and treats in and cancer patients; hyperglycosylated analogs like darbepoetin alfa, with additional N-glycan sites, exhibit prolonged serum half-life (up to threefold longer than standard EPO), allowing less frequent dosing. In vaccine development, viral glycoproteins serve as primary immunogens to elicit neutralizing antibodies. The spike glycoprotein, a trimeric surface protein, is encoded in mRNA vaccines such as BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (), which were authorized in 2020 and updated annually through 2025 to target circulating subvariants, such as those in the JN.1 lineage including KP.2 and LP.8.1, maintaining efficacy against severe disease at 70-90% in clinical trials and observational studies. These vaccines mimic the native spike structure to induce robust humoral and cellular responses, with booster formulations addressing immune escape in emerging variants. Industrial applications leverage glycoproteins for bioprocessing and manufacturing. , carbohydrate-binding glycoproteins derived from plants or microbes, are widely used in to purify therapeutic glycoproteins and by selectively binding specific motifs, enabling high-yield isolation in pharmaceutical production. Glycosidase enzymes, many of which are themselves glycoproteins, play a critical role in by hydrolyzing glycosidic bonds; for instance, β-galactosidases from microbial sources convert to glucose and in dairy products, supporting the production of lactose-free milk and improving digestibility for intolerant consumers. Recent advances in glycoengineering have optimized glycoprotein therapeutics for enhanced efficacy, including the introduction of bisected N-glycans in mAbs to augment ADCC and (CDC), with techniques like cell line engineering yielding uniform glycoforms that outperform wild-type versions in tumor clearance models. Plant-based production systems have been explored as cost-effective alternatives, for example in Medicago's CoVLP candidate, a displaying the SARS-CoV-2 spike glycoprotein produced in Nicotiana benthamiana, which showed 69.5% efficacy against symptomatic infection in phase 3 trials (2020-2022) and received conditional approval in in 2022, though it was not distributed. However, challenges persist, including immunogenicity from non-human glycans such as α-1,3-galactose or (Neu5Gc) in plant- or insect-derived products, which can trigger anti-drug antibodies in up to 20% of patients and reduce long-term efficacy. Additionally, mammalian expression systems like CHO cells, essential for human-compatible , face high production costs—often exceeding $100 per gram—due to expensive media, lengthy culture times, and scalability limitations.

Analytical Methods

Analytical methods for glycoproteins encompass a range of techniques designed to purify, detect, characterize, and quantify these heterogeneous biomolecules, often requiring integration of multiple approaches due to their structural complexity. Purification strategies frequently rely on , where such as concanavalin A (ConA) specifically bind to mannose-containing on N-linked glycoproteins, enabling selective enrichment from complex mixtures like cell lysates or biological fluids. This method exploits the reversible, carbohydrate-specific interactions of immobilized on solid supports, such as beads, to isolate glycoproteins with high specificity. Complementary to lectin-based purification, capture targets oxidized by forming stable bonds between the hydrazide-functionalized resin and aldehyde groups generated via oxidation of vicinal diols on sialic acids or other glycan residues, facilitating the isolation of glycoproteins or glycopeptides from cell surfaces or digests. Detection of glycoproteins can be achieved through electrophoretic methods like Western blotting combined with glycoprotein-specific stains, such as periodic acid-Schiff (), which oxidizes glycan vicinal diols to aldehydes that react with Schiff's reagent to produce a magenta-colored precipitate, allowing visualization of carbohydrate moieties on blotted proteins. For higher sensitivity and molecular specificity, (MS) is employed to analyze intact glycoproteins, providing mass-to-charge ratios that reveal glycoform heterogeneity, often using (ESI) coupled with high-resolution analyzers to distinguish subtle mass shifts from glycan variations. To characterize glycans, they must first be released from the protein backbone, either enzymatically or chemically. Enzymatic release commonly uses peptide:N-glycosidase F (PNGase F), which cleaves the amide bond between the innermost (GlcNAc) and residues of N-linked glycans, effectively liberating high-mannose, , and complex structures while converting the attachment site to . Chemical methods, such as hydrazinolysis, involve treating lyophilized glycoproteins with anhydrous at elevated temperatures to break the glycosidic linkages, releasing both N- and O-linked glycans as free oligosaccharides, though this approach can lead to partial degradation of reducing ends and requires subsequent cleanup. Quantification of released glycans typically involves chromatographic or electrophoretic . (HPLC), often in hydrophilic interaction (HILIC) mode, separates fluorescently labeled glycans (e.g., with 2-aminobenzamide) based on their hydrophilic interactions, enabling relative abundance determination through peak integration. (CE) provides orthogonal separation by exploiting glycan charge-to-mass ratios under an electric field, often with detection, offering high resolution for sialylated and neutral species in glycan mixtures. For site-specific analysis, liquid chromatography-tandem (LC-MS/MS) has advanced significantly in the 2020s, utilizing high-resolution instruments to fragment glycopeptides and map occupancy and microheterogeneity at individual or serine/ sites, with modes enhancing coverage of low-abundance variants. The inherent microheterogeneity of glycoproteins—arising from variable compositions, branching, and site occupancies—necessitates the use of multiple orthogonal methods to achieve comprehensive , as no single technique fully resolves all structural features without complementary validation. These analytical approaches form the foundation for glycomics studies, enabling detailed insights into glycoprotein function and diversity.

Glycomics and Structural Studies

Glycomics encompasses the systematic, large-scale analysis of glycan structures attached to glycoproteins, focusing on their diversity, composition, and functional roles within biological systems. This field examines the glycome—the entire repertoire of glycans in a , , or —revealing how these moieties influence , stability, and interactions. Unlike or , which rely on templated synthesis from genetic blueprints, glycomics grapples with non-templated, enzymatic assembly processes that generate immense structural heterogeneity, including thousands of possible glycan variants from a limited set of monosaccharides. Central to glycomics are experimental techniques for profiling and structural elucidation. Glycan arrays immobilize diverse oligosaccharides on solid supports to enable high-throughput binding studies with , antibodies, or pathogens, identifying specificity in glycan-protein interactions such as those in immune or adhesion. For atomic-level insights, (NMR) spectroscopy probes glycan dynamics and conformations in solution, while resolves three-dimensional structures of glycan-protein complexes, highlighting key hydrogen bonding and hydrophobic contacts in examples like binding to sialic acid-containing . These methods complement each other, with NMR providing motional data and crystallography offering static snapshots, though both require purified samples and can be limited by glycan flexibility. Bioinformatics resources are indispensable for interpreting glycomics data. Databases like GlycoMod predict possible compositions from experimentally determined masses via , aiding in the identification of N- or O-linked on proteins. UniCarb-DB, a curated repository of liquid chromatography-tandem (LC-MS/MS) spectra, facilitates glycan structure matching and validation through annotated fragmentation patterns from diverse biological sources. Complementary tools such as GlycoWorkbench support semi-automated annotation of mass spectra, allowing users to draw glycan structures and simulate fragmentation for sequencing. These platforms enhance reproducibility but rely on community contributions for accuracy. Advances between 2020 and 2025 have accelerated glycomics through computational and single-cell innovations. AI-driven models, building on extensions, now predict glycan conformations and interactions with proteins by incorporating diffusion-based architectures that handle flexibility, achieving near-experimental accuracy for complexes like glycosyltransferases with donor sugars. Single-cell glycomics techniques, such as CyTOF-Lec ( with probes) and scGR-seq (single-cell and sequencing), enable profiling of heterogeneity across individual , uncovering variations in immune glycosylation linked to states like cancer. These developments integrate glycomics with multi-omics, fostering discoveries in . Despite progress, glycomics faces persistent challenges from glycan structural complexity. Isomerism—arising from identical compositions with differing linkages or anomeric configurations—and branching patterns complicate unambiguous identification, often requiring orthogonal methods like enzymatic or NMR for . Incomplete databases further hinder , as many rare or species-specific lack spectra, leading to underrepresentation in analyses and gaps in functional predictions. Addressing these requires expanded curation and hybrid experimental-computational approaches to capture glycan diversity fully.

Distinction from Proteoglycans

Glycoproteins and proteoglycans are both classes of conjugated proteins featuring covalently attached moieties, but they differ fundamentally in the nature and extent of their . Glycoproteins typically bear short, branched chains consisting of 1 to 20 units, often N-linked to residues or O-linked to serine or . In contrast, proteoglycans are characterized by long, unbranched (GAG) chains, each comprising 50 to 200 repeating units, such as those found in hyaluronan or , which can exceed 20 kDa in size. These GAG chains dominate the , often accounting for over 95% of the total carbohydrate content in proteoglycans, distinguishing them from the more protein-dominant structure in most glycoproteins. The attachment mechanisms further highlight these distinctions, though both classes utilize O- and N-glycosidic linkages. In glycoproteins, glycans are directly coupled to the protein core via these bonds, as exemplified by mucins, which feature dense clusters of O-linked oligosaccharides for mucosal protection and lubrication. Proteoglycans, however, attach GAG chains through a specific tetrasaccharide linker (xylose-galactose-galactose-glucuronic acid) to serine residues, often in clustered Ser-Gly motifs, enabling the extension of linear polymers; aggrecan, a major proteoglycan in , illustrates this with over 100 chains that provide compressive resilience. This specialized linkage supports the polyanionic properties of GAGs, which are sulfated and interact electrostatically with water and proteins. Functionally, glycoproteins primarily mediate cell-cell recognition, signaling, and immune responses through their diverse, information-rich structures. , by virtue of their extended chains, contribute to () organization, hydration, and mechanical support; for instance, aggrecan aggregates with hyaluronan to form hydrated gels that endow with load-bearing capacity. Despite these differences, overlaps exist in hybrid molecules like serglycin, an intracellular proteoglycan in hematopoietic cells that carries both GAG chains (e.g., or ) and shorter glycoprotein-like oligosaccharides, bridging the two categories. Proteoglycans are considered a specialized subset of glycoproteins due to their shared core protein-glycan architecture, but the emphasizes the predominance of GAGs, which impart unique biophysical properties not typical of standard glycoproteins. Evolutionarily, both classes trace back to ancient metazoan origins, with shared families (e.g., GT2 and GT47 superfamilies) facilitating the assembly of their respective glycans, suggesting divergent adaptation from common enzymatic machinery for ECM and cell surface modulation.

References

  1. [1]
    Historical Background and Overview - Essentials of Glycobiology
    A glycoprotein is a glycoconjugate in which a protein carries one or more glycans covalently attached to a polypeptide backbone, usually via N- or O-linkages.
  2. [2]
    The multiple evolutionary origins of the eukaryotic N-glycosylation ...
    Aug 4, 2016 · N-glycosylation in the three domains of life. More than half of all eukaryotic proteins are glycoproteins, and 90 % of those are N-glycosylated ...
  3. [3]
    Biological Functions of Glycans - Essentials of Glycobiology - NCBI
    Glycans have structural roles in, on, and outside cells; energy metabolism; and act as information carriers through specific recognition.BIOLOGICAL... · STRUCTURAL FUNCTIONS... · GLYCANS AS INFORMATION...
  4. [4]
    Historical Background and Overview - Essentials of Glycobiology - NCBI Bookshelf
    ### Summary of Glycoprotein Information from Essentials of Glycobiology (Chapter 1)
  5. [5]
  6. [6]
    GLYCOPROTEIN definition in American English - Collins Dictionary
    Word origin. [1905–10; glyco- + protein]. COBUILD frequency band. glycoprotein in British English. (ˌɡlaɪkəʊˈprəʊtiːn IPA Pronunciation Guide ), glucoprotein or ...
  7. [7]
    Decoding glycans: deciphering the sugary secrets to be coherent on ...
    Sep 15, 2020 · Glycans are chains of monosaccharide units, varying in length from a few sugars to several hundreds.
  8. [8]
    Glycoprotein - an overview | ScienceDirect Topics
    A glycoprotein is a type of conjugated protein with shorter, branched carbohydrate chains known as oligosaccharides. They are part of various biological ...
  9. [9]
    N-Linked Glycosylation - an overview | ScienceDirect Topics
    N-linked glycosylation is the attachment of polysaccharide chains to asparagine residues in proteins, essential for protein folding, quality control, and ...
  10. [10]
    Unusual Protein Glycosylation: Beyond Sequon & Amino Acids
    Conventional N-glycosylation occurs through the recognition of the consensus sequon, asparagine (Asn)-X-serine (Ser)/threonine (Thr), where X is any amino acid ...
  11. [11]
    Glycosylation: mechanisms, biological functions and clinical ... - Nature
    Aug 5, 2024 · The amino acids and glycans are classified into four categories according to their linkage: O-glycosylation, N-glycosylation, C-glycosylation ...
  12. [12]
    Methods in enzymology: O-glycosylation of proteins - PubMed
    The most abundant type of O-glycosylation in proteins is the GalNAc attachment to serine (Ser) or threonine (Thr) in the protein chain by an a-glycosidic ...
  13. [13]
    O-Linked Glycosylation - an overview | ScienceDirect Topics
    In O-linked glycosylation, the glycan is attached to the serine/threonine side chain [24]. O-linked glycosylation usually starts with an N-acetylgalactosamine ( ...
  14. [14]
    Hydroxylysine - an overview | ScienceDirect Topics
    The hydroxylysine residues provide the sites for α-O-glycosidic linkage with galactose or glucose or α(1→2) glucosylgalactose. The collagens differ in their ...
  15. [15]
    Mimivirus Collagen Is Modified by Bifunctional Lysyl Hydroxylase ...
    Collagens, the most abundant proteins in animals, are modified by hydroxylation of proline and lysine residues and by glycosylation of hydroxylysine.<|separator|>
  16. [16]
    Advances in understanding N-glycosylation structure, function, and ...
    This review discusses the diverse structure of N-linked glycans, the function and regulation of N-glycosylation in health and diseaseMissing: linkages | Show results with:linkages
  17. [17]
    Meta-heterogeneity: Evaluating and Describing the Diversity in ...
    Macro-heterogeneity describes the variation in glycosylation site occupancy and micro-heterogeneity the variation in glycan species, but these are not ...Missing: variability | Show results with:variability
  18. [18]
    Effect of glycosylation on protein folding
    Jun 20, 2025 · N-glycosylation influences protein folding directly through the structural attributes of the glycans attached. Typically, these glycans are ...
  19. [19]
    Folding of glycoproteins: toward understanding the biophysics of the ...
    In this article, we discuss how the size, number, and structure of glycans, as well as the attachment sites, may modulate the folding of glycoproteins.
  20. [20]
    Effects of N-glycosylation on protein conformation and dynamics
    Mar 9, 2015 · Our study reveals that N-glycosylation does not induce significant changes in protein structure, but decreases protein dynamics, likely leading to an increase ...Missing: implications | Show results with:implications
  21. [21]
    Monosaccharide Diversity - Essentials of Glycobiology - NCBI - NIH
    Monosaccharides are the simplest polyhydroxylated carbonyl compounds, with chiral hydroxymethylene units, and are the basic building blocks of glycans.
  22. [22]
    Tools for Mammalian Glycoscience Research - PMC - PubMed Central
    In vertebrates, glycans are composed of nine main monosaccharide building blocks: glucose (Glc), galactose (Gal), xylose (Xyl), mannose (Man), fucose (Fuc), N- ...A Brief Guide To Glycans And... · Identifying Relevant Glycan... · Generating Chemically...<|control11|><|separator|>
  23. [23]
  24. [24]
    N-Linked Protein Glycosylation in the Endoplasmic Reticulum - PMC
    The buildup of the glycan is initiated at the cytoplasmic leaflet of the ER membrane by the addition of N-acetylglucosamine (GlcNAc)-phosphate to dolichol- ...
  25. [25]
    O-GalNAc Glycans - Essentials of Glycobiology - NCBI Bookshelf - NIH
    O-GalNAc glycans are involved in almost every aspect of biology, including cell–cell communication, cell adhesion, signal transduction, immune surveillance.
  26. [26]
    N-Glycans - Essentials of Glycobiology - NCBI Bookshelf
    N-Glycans are covalently attached to protein at asparagine (Asn) residues by an N-glycosidic bond. Although diverse sugars are attached to Asn in prokaryotes.
  27. [27]
  28. [28]
    Biological functions of fucose in mammals - PMC - NIH
    Fucose is an unusual sugar that is present in a variety of glycolipids and glycoproteins produced by mammalian cells. It is unique in having an l-configuration, ...
  29. [29]
    Glycosylation Precursors - Essentials of Glycobiology - NCBI - NIH
    Most glycans are synthesized by glycosyltransferases, enzymes that transfer activated forms of monosaccharides from nucleotide sugars and lipid-linked sugar ...
  30. [30]
    N-Glycans - Essentials of Glycobiology - NCBI Bookshelf
    Included is an overview of the mechanisms in N-glycan formation, processing, control of protein folding, and structural diversification. Also presented is a ...
  31. [31]
    Global mapping of GalNAc-T isoform-specificities and O ... - Nature
    Oct 21, 2022 · Here we present a systematic analysis of the isoform-specific targets of all GalNAc-Ts expressed within a tissue-forming human skin cell line.
  32. [32]
    Glycobiology of α-dystroglycan and muscular dystrophy
    Nov 7, 2014 · In this review, I will describe the structures and biosynthetic pathways of O-mannosyl glycans and the relationship between muscular dystrophy and α-DG ...Dystroglycan · O-Mannosyl Glycan... · O-Mannosyl Glycan Structures
  33. [33]
    Regulation of Notch Signaling by O-Linked Fucose - ScienceDirect
    We demonstrate that O-linked fucose is positively required for Notch signaling, including both Fringe-dependent and Fringe-independent processes.Missing: fucosyl | Show results with:fucosyl
  34. [34]
    O-GlcNAc transferase and O-GlcNAcase: achieving target substrate ...
    O-GlcNAc cycling on nucleocytosolic and mitochondrial proteins is controlled by only two genes, encoding O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) which ...
  35. [35]
    Glycosylphosphatidylinositol Anchors - Essentials of Glycobiology
    This chapter reviews the discovery, distribution, structure, biosynthesis, properties, and suggested functions of GPI anchors and related molecules
  36. [36]
    Glycosylphosphatidylinositol (GPI) Anchors: Biochemistry and Cell ...
    The GPI anchor represents a posttranslational modification of proteins with a glycolipid and is used ubiquitously in eukaryotes and most likely in some Archaea, ...
  37. [37]
    Review Glycosylation in Cellular Mechanisms of Health and Disease
    Sep 8, 2006 · Paroxysmal nocturnal hemoglobinuria usually occurs in adulthood and results from somatic mutation within the bone-marrow stem cell population ...
  38. [38]
    Molecular basis of C‐mannosylation – a structural perspective
    Nov 6, 2021 · Here, we present the first comprehensive review of C-mannosylated protein structures by analysing the data for all 10 proteins with C- ...Abstract · Introduction · Results · Discussion
  39. [39]
    C-mannosylation supports folding and enhances stability of ... - eLife
    Dec 23, 2019 · C-mannosylation supports native folding of thrombospondin type 1 repeats in the endoplasmic reticulum and stabilizes the folded proteins by ...
  40. [40]
  41. [41]
    Bacterial phosphoglycosyl transferases: initiators of glycan ...
    Phosphoglycosyl transferases (PGTs) initiate the biosynthesis of both essential and virulence-associated bacterial glycoconjugates.
  42. [42]
    O-GlcNAcylation and O-GlcNAc Cycling Regulate Gene Transcription
    We will focus on the complex relationship between phosphorylation and O-GlcNAcylation in the regulation of the RNA Polymerase II (RNAP II) pre-initiation ...Missing: Phosphoglycosylation | Show results with:Phosphoglycosylation
  43. [43]
    Selectins: initiators of leucocyte adhesion and signalling at the ... - NIH
    The selectins are transmembrane, Ca2+-dependent lectins that mediate leucocyte rolling on vascular surfaces, the first adhesive step during inflammation and ...
  44. [44]
    Glycosylation Modulates the Structure and Functions of Collagen
    Although not fully understood, it is clear that the glycosylation of collagens influences collagen secretion and the alignment of collagen fibrils.
  45. [45]
    Collagen's enigmatic, highly conserved N-glycan has an essential ...
    Mar 5, 2021 · Outside the cell, N-glycans can mediate protein–protein interactions, stabilize and/or organize extracellular matrices, and provide protection ...
  46. [46]
    Mucins in the mucosal barrier to infection - Nature
    Mar 5, 2008 · In this review, we highlight the central role played by mucins in accommodating the resident commensal flora and limiting infectious disease.
  47. [47]
    N-Glycosylation as determinant of epidermal growth factor receptor ...
    We find that N-glycosylation is a critical determinant of EGFR conformation, and specifically the orientation of the EGFR ectodomain relative to the membrane.
  48. [48]
    The glycosylation design space for recombinant lysosomal ... - NIH
    Apr 30, 2019 · ... (half-life 27.5 ± 0.8 min) (Fig. 5c) and lower enzyme activity in the liver, spleen, and kidney, but the highest level of enzyme in the heart ...
  49. [49]
    Glycosyltransferase complexes in eukaryotes - PubMed Central - NIH
    Glycosylation is the most common and complex cellular modification of proteins and lipids. It is critical for multicellular life and its abrogation often ...
  50. [50]
    Towards understanding the extensive diversity of protein N‐glycan ...
    Dec 6, 2021 · In this review, we mainly focus on N-glycosylation pathways in eukaryotes, describing the main steps leading to the extensive diversity of N ...
  51. [51]
    Golgi Glycosylation - PMC - PubMed Central - NIH
    The initiation of O-glycosylation also occurs in the ER for most O-glycans and consists of the addition of only a single sugar residue to Ser or Thr. The most ...
  52. [52]
    Contrasting Functions of Calreticulin and Calnexin in Glycoprotein ...
    Thus, the components of the calnexin/calreticulin cycle are central players in the retention machinery underlying glycoprotein quality control. Experimental ...
  53. [53]
    Calnexin cycle – structural features of the ER chaperone system
    Apr 13, 2020 · Recent structures of components of the calnexin cycle have deepened our understanding of quality control mechanisms and protein folding pathways ...
  54. [54]
  55. [55]
    The dolichol pathway of N-linked glycosylation - PubMed
    Jan 6, 1999 · In this review, we discuss the function of the lipid carrier dolichol in oligosaccharide assembly and give an overview of the biosynthesis of the different ...
  56. [56]
    New insights into the physiological role of ERAD - PMC - NIH
    ER-associated degradation (ERAD) is a principal quality-control mechanism responsible for targeting misfolded ER proteins for cytosolic degradation.
  57. [57]
    Protein Glycoengineering: An Approach for Improving ... - Frontiers
    Jul 22, 2020 · Scientists have also chosen many different types of non-mammalian cells for protein glycoengineering, including plant, insect, yeast, and ...
  58. [58]
    A concise guide to choosing suitable gene expression systems for ...
    Dec 15, 2023 · This guide uses a decision scheme with four key questions based on protein characteristics to select the most suitable gene expression system.
  59. [59]
    Platforms for Recombinant Therapeutic Glycoprotein Production
    This chapter covers the general aspects of therapeutic recombinant glycoproteins and the platforms that are being employed for their production. Keywords: ...
  60. [60]
    Glycosylation control technologies for recombinant therapeutic ...
    Oct 17, 2018 · This review summarizes the recent technologies used for the improvement of the glycan composition of the biotherapeutics.<|control11|><|separator|>
  61. [61]
    Expression systems for therapeutic glycoprotein production - PubMed
    The need for expression systems allowing the efficient manufacturing of high quality glycoproteins is thus becoming imperative.
  62. [62]
    Cell-Free Synthetic Glycobiology: Designing and Engineering ...
    Cell-free synthetic glycobiology has emerged as a simplified and highly modular framework to investigate, prototype, and engineer pathways for glycan ...
  63. [63]
    Advances in bacterial glycoprotein engineering: A critical review of ...
    Jan 2, 2025 · This review outlines the recent advances in bacterial protein glycosylation from the perspective of synthetic biology and metabolic engineering
  64. [64]
  65. [65]
    Leloir Glycosyltransferases in Applied Biocatalysis - NIH
    Leloir glycosyltransferases utilize carbohydrates linked to a nucleotide diphosphate (NDP) with an α-linked glycosidic bond, where non-Leloir glycosyl ...
  66. [66]
    Importance of glycosidases in mammalian glycoprotein biosynthesis
    Dec 6, 1999 · Processing glycosidases play an important role in N-glycan biosynthesis in mammalian cells by trimming Glc(3)Man(9)GlcNAc(2) and thus providing the substrates ...
  67. [67]
    The role of nucleotide sugar transporters in development of eukaryotes
    1.3. Transport of nucleotide sugars regulates glycosylation of macromolecules. Evidence supports the hypothesis that transport of nucleotide sugars into the ...1. Introduction · Fig. 1 · Fig. 2
  68. [68]
    N-glycan based ER molecular chaperone and protein quality control ...
    Calnexin and calreticulin bind and influence the maturation of a large number of proteins as they traffic through the ER and many of these client proteins are ...
  69. [69]
    Understanding glycosylation: Regulation through the metabolic flux ...
    GNE can bind to UDP-GlcNAc, its substrate, and CMP-Neu5Ac, which causes feedback inhibition by binding to an allosteric site (Chen et al., 2016). Following the ...
  70. [70]
    The post-translational modification O-GlcNAc is a sensor and ... - NIH
    Oct 30, 2024 · Specifically, we discuss the mechanisms of elevated O-GlcNAc levels in contributing to diabetes and cancer, as well as the role of decreased O- ...<|control11|><|separator|>
  71. [71]
    Dysregulation of TGF-β1 receptor activation leads to abnormal lung ...
    Oct 25, 2005 · Histopathological analysis revealed that Fut8-/- mice showed emphysema-like changes in the lung, verified by a physiological compliance analysis ...
  72. [72]
    ABO blood group antigens and differential glycan expression
    Jan 20, 2023 · In this review, we examine the enzymes responsible for carbohydrate-based blood group antigen biosynthesis and their expression within the human population.
  73. [73]
    Chemical characterization and distribution of ABO blood ... - PubMed
    Jun 25, 1976 · Chemical characterization and distribution of ABO blood group active glycoprotein in human erythrocyte membrane.
  74. [74]
    The O-linked glycosylation of secretory/shed MUC1 from ... - PubMed
    MUC1 is a high molecular weight glycoprotein that is overexpressed in breast cancer. Aberrant O-linked glycosylation of MUC1 in cancer has been implicated ...
  75. [75]
    Glycosylated modification of MUC1 maybe a new target to promote ...
    Aug 16, 2022 · MUC1 is a highly glycosylated transmembrane protein, overexpressed in breast cancer, contributing to tumorigenesis and worse prognosis.
  76. [76]
    Red Blood Cell Glycophorins - ScienceDirect.com
    GPA, with its high sialic acid content, is the major contributor to the net negative surface charge of the mature RBC membrane. This underappreciated biologic ...
  77. [77]
    Human erythrocyte glycophorins: protein and gene structure analyses
    Human RBCs glycophorins are integral membrane proteins rich in sialic acids that carry blood group antigenic determinants and serve as ligands for viruses, ...Missing: red cells
  78. [78]
    Multivalent interactions between fully glycosylated influenza virus ...
    Oct 17, 2024 · The hemagglutinin (HA) glycoprotein of influenza virus binds host cell receptors and mediates viral entry.
  79. [79]
    Entry of influenza A virus into host cells — recent progress and ...
    Apr 7, 2021 · N-linked glycosylation facilitates sialic acid-independent attachment and entry of influenza A viruses into cells expressing DC-SIGN or L-SIGN.
  80. [80]
    Mapping N-Glycosylation Sites across Seven Evolutionarily Distant ...
    May 25, 2012 · We find that all eukaryotic N-glycoproteomes have invariant characteristics including sequence recognition patterns, structural constraints, and subcellular ...
  81. [81]
    Microbial glycoproteomics - ScienceDirect
    Many prokaryotes display abundant surface exposed glycoproteins such as pilins, flagella and S-layer proteins that can be separated and purified for both bottom ...
  82. [82]
    Synthesis and secretion of gonadotropins including structure ... - NIH
    The glycoprotein hormone family includes luteinizing hormone (LH), follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH) and chorionic ...
  83. [83]
    Structure–Function Relationships of Glycoprotein Hormones and ...
    Feb 26, 2015 · In the present report, we review the available structural and functional data concerning GPHs and their subunits' ancestors.
  84. [84]
    Follicle-Stimulating Hormone Glycobiology - PMC - PubMed Central
    FSH biological activity in the gonads is dependent on glycosylation, not only as a critical factor in determining survival in the circulation (9), but also in ...Fsh Glycosylation... · Figure 3 · References And Notes
  85. [85]
    Functional Consequences of Mannose and Asialoglycoprotein ... - NIH
    The ManR clears LH thus regulating testosterone production, whereas the ASGR appears to mediate clearance of an unidentified glycoprotein that increases LH ...
  86. [86]
    hCG: Biological Functions and Clinical Applications - PMC
    Sep 22, 2017 · The half-life of injected purified hCG conformed to a biphasic pattern (rapid phase: 5–6 h and slower phase: 24–33 h) [60,62], whereas that of ...2. Structure, Isoforms, And... · 3. Role Of Hcg In Embryo... · 7. Conclusions
  87. [87]
    Hormonal Regulation of Follicle-Stimulating Hormone Glycosylation ...
    Jan 29, 2019 · Hormonal factors, mainly GnRH and androgens, are involved in the regulation of FSH oligosaccharide structure, as demonstrated in rodents and ...Missing: LH | Show results with:LH
  88. [88]
    Regulation of Reproduction via Tight Control of Gonadotropin ... - NIH
    GnRH from the hypothalamus regulates synthesis and secretion of gonadotropins, LH and FSH, which then control steroidogenesis and gametogenesis.
  89. [89]
    Recombinant follitropin alfa/lutropin alfa in fertility treatment - PMC
    Follitropin alpha can be used for controlled ovarian hyperstimulation in assisted reproduction, ovulation induction for WHO group I and II anovulatory ...
  90. [90]
    Human Recombinant FSH and Its Biosimilars: Clinical Efficacy ... - NIH
    Jun 27, 2020 · Medications containing hFSH have been used for decades to treat infertile women with anovulatory cycles or to accomplish controlled ovarian ...
  91. [91]
    Control of recombinant monoclonal antibody effector functions by Fc ...
    In this study we have specifically remodeled the Fc N-glycans of intact recombinant IgG(1) therapeutic monoclonal antibody (Mab) products, Rituxan and Herceptin ...
  92. [92]
    Glycoengineering of Antibodies for Modulating Functions - PMC - NIH
    All antibodies are glycoproteins that carry at least one or more conserved N-linked oligosaccharides (N-glycans) at the Fc domain. Many studies have ...<|separator|>
  93. [93]
    Erythropoiesis stimulating agents: approaches to modulate activity
    Jul 3, 2013 · Darbepoetin alfa is a hyperglycosylated analogue of rHuEPO, has been approved for the treatment of anemia associated with chronic renal ...
  94. [94]
    SARS-CoV-2 Vaccines, Vaccine Development Technologies, and ...
    Mar 17, 2023 · The authorized mRNA vaccines are the Moderna and Pfizer–BioNTech vaccines; conventional inactivated vaccines include CoronaVac, Covaxin, BBIBP- ...
  95. [95]
    The evolution of SARS-CoV-2 | Nature Reviews Microbiology
    Apr 5, 2023 · This Review explores the mechanisms that generate genetic variation in SARS-CoV-2, underlying the within-host and population-level processes that underpin ...<|separator|>
  96. [96]
  97. [97]
    Glycosidases: a key to tailored carbohydrates - ScienceDirect
    In recent years, carbohydrate-processing enzymes have become the enzymes of choice in many applications thanks to their stereoselectivity and efficiency.
  98. [98]
    Recent advances in antibody glycoengineering for the gain of ...
    Here, we review the recent approaches to achieve glycoengineered antibodies, including the genetic engineering of the expression system, the in vitro chemo- ...Missing: bisected approvals
  99. [99]
    Efficacy and Safety of a Recombinant Plant-Based Adjuvanted ...
    May 4, 2022 · The CoVLP+AS03 vaccine was effective in preventing Covid-19 caused by a spectrum of variants, with efficacy ranging from 69.5% against symptomatic infection to ...
  100. [100]
    Immunogenicity of glycans on biotherapeutic drugs produced in ...
    This study shows the benefit of using large scale human trials to evaluate the immunogenicity risk of plant derived glycans.
  101. [101]
    Challenges in therapeutic glycoprotein production - ScienceDirect.com
    Mammalian cell culture, which is currently the production system of choice for glycoproteins, has several disadvantages including high cost of goods, long cycle ...
  102. [102]
    Lectin-Based Affinity Enrichment and Characterization of N ... - NIH
    Jan 8, 2023 · The present study aimed to develop a lectin-based affinity method for the enrichment and concentration of tear glycoproteins/glycopeptides and to characterize ...
  103. [103]
    Lectin affinity chromatography and quantitative proteomic analysis ...
    Oct 5, 2020 · In this study, two immobilized lectin affinity chromatography (ConA and WGA) normally used to enrich glycoproteins were applied to two different ...
  104. [104]
    Glycan Analysis by Reversible Reaction to Hydrazide Beads ... - NIH
    In this method, glycosylated peptides from digested glycoproteins are captured by using hydrazide beads after glycans on glycopeptides are oxidized.
  105. [105]
    Periodic acid/Schiff staining of glycoproteins immobilized on a ...
    A simple and sensitive method for the detection of glycoproteins and glycopeptides in solution and in polyacrylamide gels is described, which combines the ...
  106. [106]
    Intact glycopeptide characterization using mass spectrometry - PMC
    In this review, we recapitulated currently available intact glycopeptide characterization methods with respect to their advantages and limitations as well as ...
  107. [107]
    N-linked Glycan Release Efficiency: A Quantitative Comparison ...
    One of the most common enzymatic release methods is the use of peptide:N-glycosidase F (PNGase F). A less expensive and quicker alternative has been reported ...
  108. [108]
    Release of N-glycans by hydrazinolysis - NCBI - NIH
    Aug 24, 2021 · Hydrazinolysis, differing from an enzymatic procedure to liberate glycans from glycoproteins, is not essentially influenced by chemical ...
  109. [109]
    Glycan analysis of therapeutic glycoproteins - PMC - NIH
    HPLC is widely used to quantify the amounts of released oligosaccharides. MS coupled with HPLC remains a powerful tool in the characterization of glycosylation ...
  110. [110]
    Capillary Electrophoresis Separations of Glycans | Chemical Reviews
    Capillary electrophoresis methods have been developed that are capable of separating glycans with the same monosaccharide sequence but different positional ...Introduction · Background · Methods To Identify Glycans · Applications
  111. [111]
    Methods for quantification of glycopeptides by liquid separation and ...
    Jan 31, 2022 · We discuss the sample preparation procedures and the mass spectrometry (MS) strategies that have facilitated glycopeptide quantification, as well as the ...
  112. [112]
    Relating glycoprotein structural heterogeneity to function
    Jul 18, 2019 · Native mass spectrometry helps characterize glycoproteins, relate glycan structure to function, and provides structural information not ...
  113. [113]
  114. [114]
    The Challenge and Promise of Glycomics - Cell Press
    Jan 16, 2014 · Glycomics is a broad and emerging scientific discipline focused on defining the structures and functional roles of glycans in biological systems.
  115. [115]
    Glycomics - Glycopedia
    In analogy with genomics and proteomics, the systematic study of the glycome is called glycomics. In contrast to proteins, glycans cannot be directly predicted ...
  116. [116]
    Glycan Arrays: Recent Advances and Future Challenges - PMC - NIH
    Carbohydrate arrays, also referred to as glycan arrays, are composed of various oligosaccharides and/or polysaccharides immobilized on a solid support in a ...
  117. [117]
    Cell-based glycan arrays for probing glycan–glycan binding protein ...
    Feb 28, 2018 · Glycan microarrays provide a high-throughput means of profiling the interactions of glycan-binding proteins with their ligands.
  118. [118]
    Structural Biology of Glycan Recognition - Essentials of Glycobiology
    X-ray crystallography is a very powerful method for obtaining details of protein–ligand interactions. It excels in terms of the size range of molecules that can ...
  119. [119]
    saturation-transfer difference NMR and X-ray crystallography ...
    Aug 1, 2018 · It exemplifies how crystallography and STD-NMR can be combined to elucidate protein-glycan (and other protein-ligand) interactions in atomic ...
  120. [120]
    GlycoMod - Expasy
    GlycoMod is a tool that can predict the possible oligosaccharide structures that occur on proteins from their experimentally determined masses.Mass values · Documentation · References
  121. [121]
    UniCarb-DB: a database resource for glycomic discovery
    UniCarb-DB: a database resource for glycomic ... These high-quality databases are capable of providing detailed information about the individual glycans ...
  122. [122]
    UniCarb-DB
    UniCarb-DB provides access to a collection of manually annotated spectra that have been experimentally verified in order to increase the speed and accuracy of ...
  123. [123]
    GlycoWorkbench: A Tool for the Computer-Assisted Annotation of ...
    GlycoWorkbench is a software tool developed by the EUROCarbDB initiative to assist the manual interpretation of MS data.
  124. [124]
    Accurate structure prediction of biomolecular interactions ... - Nature
    May 8, 2024 · Here we describe our AlphaFold 3 model with a substantially updated diffusion-based architecture that is capable of predicting the joint structure of complexes.Missing: extensions | Show results with:extensions
  125. [125]
    Modeling glycans with AlphaFold 3: capabilities, caveats, and ... - NIH
    Aug 28, 2025 · Glycan interactions were also modeled with glycosylation enzymes and lectins with benchmarking and validation against known crystal structures.
  126. [126]
    Native N-glycome profiling of single cells and ng-level blood isolates ...
    May 8, 2024 · Single-cell glycomics analysis by CyTOF-Lec ... Recent advances in analytical methods and bioinformatic tools for quantitative glycomics.
  127. [127]
    Emerging technologies for single-cell glycomics - ScienceDirect.com
    Recently, we developed a novel technology called single-cell glycan and RNA sequencing (scGR-seq), which converts glycan information into genetic information ...
  128. [128]
    Glycomics in Human Diseases and Its Emerging Role in Biomarker ...
    Glycan structural complexity poses significant challenges for identification, largely due to isomerism arising from variations in branching, linkage, and ...
  129. [129]
    High-Throughput Glycomic Methods | Chemical Reviews
    Jul 7, 2022 · One of the challenges of vast glycomics data generation and integration with databases, is its complexity in terms of nonuniform glycan ...
  130. [130]
  131. [131]
    The Challenge and Promise of Glycomics - PMC - NIH
    Abstract. Glycomics is a broad and emerging scientific discipline focused on defining the structures and functional roles of glycans in biological systems.
  132. [132]
    Proteoglycans and Glycosaminoglycans - Essentials of Glycobiology
    ... Karl Meyer and his associates, who described the structure of hyaluronic acid, dermatan sulfate, keratan sulfate, and different isomeric forms of ...
  133. [133]
    Proteoglycans: a special class of glycoproteins - ScienceDirect.com
    Proteoglycans are defined by their structure as a type of glycoprotein that has covalently linked large polysaccharide (glycosaminoglycan) chains composed of ...
  134. [134]
    [PDF] Complex Carbohydrates 1. Proteoglycans 2. Glycoproteins
    Proteoglycans may be soluble and located in the extra-cellular matrix, or they may be integral transmembrane proteins. 2. Proteoglycans may modulate cell growth ...
  135. [135]
    Serglycin Is a Major Proteoglycan in Polarized Human Endothelial ...
    Secreted serglycin was identified by immunoprecipitation as a PG with a core protein of ∼30 kDa. Serglycin was furthermore shown to be present in perinuclear ...
  136. [136]
    Evolution of glycosaminoglycans and their glycosyltransferases ...
    Oct 14, 2002 · The three types of glycosyltransferases appear to have evolved independently based on sequence comparisons and other characteristics.